Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 04 10; 36(11):1080-1087.

View in: PubMed

subject areas

Androgen Antagonists
Antineoplastic Combined Chemotherapy Protocols
Humans
Male
Neoplasm Metastasis
Neoplasms, Hormone-Dependent
Prostatic Neoplasms
Time Factors
Treatment Outcome

authors with profiles

Daniel H. Shevrin